Genmab — August 2015
-
Ser ud til at der bettes på et godt regnskab
-
aktien holder flot oppe i et meget negativt marked
-
devalueret Yuan styrker $ overfor Yuan. $ er nede overfor Euro og DKK
-
devalueret Yuan betyder jo at fremtidigt salg i kina bliver 2% mindre værd i DKK
-
ja det har ikke meget påvirkning. Min kommentar var mere en respons til bulder der mente at Yuan devaluering overfor $ ville give $/EUR et løft hvilket ikke rigtigt gav mening
-
Orphan altid godt fordi det ofte fører til fast track/priority review i godkendelsesprocessen samt høje priser ved salg
-
Resultat ude . 25 mio. $ i milestone i kvartalet luner godt
-
fastholder FYE, ellers ikke noget at berette fra H1
-
3 mia. DKK i Cash
-
Arzerra continues to face intense competition and given the competitive
market, we have reduced our estimate of Arzerra royalties to DKK 100 million from our previous estimate
of DKK 125 million. -
Arzerra continues to face intense competition and given the competitive
market, we have reduced our estimate of Arzerra royalties to DKK 100 million from our previous estimate
of DKK 125 million. -
June: An expanded access program for daratumumab was opened for eligible patients in the
U.S. by Janssen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind